Vifor Pharma (VIFN.SW) Osake Kurssi
Vifor Pharma Kurssi
Vifor Pharman liikevaihto on supistunut 1,2 % vuodessa viimeisten 19 vuoden aikana 1,82 Mrd. CHF:een. Osakekohtainen tulos on kasvanut 5,4 % vuodessa viimeisten 19 vuoden aikana. Vifor Pharman nettomarginaali 7,9 % on laskenut verrattuna 85,5 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 1,20 %. Jakosuhde on noin 81 % tuloksesta. Osinko on kasvanut 10,5 % vuodessa viimeisten 18 vuoden aikana.
Vifor Pharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Vifor Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Vifor Pharma -osakkeesta
The business model of Vifor Pharma AG focuses on the development, production, and commercialization of pharmaceutical products. As a global healthcare company, Vifor Pharma AG specializes in the field of iron deficiency, nephrology, and cardio-renal therapies. They aim to improve the quality of life for patients suffering from various medical conditions, including chronic kidney disease, iron deficiency anemia, and renal diseases. Vifor Pharma AG collaborates with healthcare professionals and organizations worldwide to bring innovative and effective treatments to market. By leveraging their expertise and research capabilities, Vifor Pharma AG continues to drive advancements in the field of pharmaceuticals and improve patient outcomes.
Vifor Pharma AG is primarily active in the pharmaceutical industry.
The main competitors of Vifor Pharma AG in the market include companies like Novartis, Roche, Sanofi, and AstraZeneca. These companies operate in similar therapeutic areas and engage in the development and commercialization of pharmaceutical products. Vifor Pharma AG competes with these companies through its innovative and high-quality offerings, strategic partnerships, and strong market presence. By continuously adapting and expanding its product portfolio, Vifor Pharma AG aims to maintain its competitive position within the pharmaceutical industry.
Vifor Pharma AG, a leading global pharmaceutical company, has a rich history and background. Established in 1872 and headquartered in Switzerland, Vifor Pharma focuses on innovative treatments for patients suffering from iron deficiency, nephrology, and cardio-renal disorders. The company has played a pivotal role in healthcare advancements, leveraging its expertise to develop high-quality and effective pharmaceutical products. Vifor Pharma operates globally, collaborating with healthcare professionals to improve patients' well-being. Committed to research, development, and sustainable growth, Vifor Pharma aims to enhance the lives of individuals worldwide through its innovative solutions in the medical field.
Vifor Pharma AG, a renowned pharmaceutical company, has achieved several significant milestones throughout its existence. Notably, it successfully developed and launched a groundbreaking medication for the treatment of iron deficiency anemia (IDA) called Ferinject®. This innovative intravenous iron replacement therapy has transformed patient care worldwide. Vifor Pharma AG has also made strides in the field of nephrology, advancing the treatment of chronic kidney disease (CKD) and associated complications. With a strong focus on research and development, Vifor Pharma AG continues to seek out new therapeutic options and strategic partnerships to further enhance patient outcomes and improve global healthcare.
Vifor Pharma AG is primarily present in various countries and regions worldwide. Its presence can be seen in Europe, North America, and certain parts of Asia. The company operates in diverse markets, including Switzerland, Germany, Austria, France, the United Kingdom, the United States, China, and Japan. With a global reach, Vifor Pharma AG has established itself as a leading pharmaceutical player in these regions, offering innovative healthcare solutions and improving patient outcomes.
Vifor Pharma AG represents a set of core values and corporate philosophy that guides its operations. The company's values include a strong commitment to patients, healthcare providers, and employees. Vifor Pharma AG strives to make a positive impact on patients' lives through innovative healthcare solutions. The company's corporate philosophy centers around trust, integrity, and excellence. Vifor Pharma AG focuses on continuous improvement and delivering value to its stakeholders. With a patient-centric approach, Vifor Pharma AG aims to enhance patient outcomes and drive sustainable growth in the pharmaceutical industry.
11 analyytikkoa arvioi tällä hetkellä Vifor Pharma-osaketta: 0 suosittaa ostoa, 4 pitoa ja 7 myyntiä.
Nykyisellä valuuttakurssilla Vifor Pharma-osake noteerataan hintaan 180,57 EUR (166,15 CHF).
Vifor Pharma-osake (VIFN.SW) on listattuna 5 pörssissä, muun muassa: London (0RPD.L), SIX (Zürich) (VIFN.SW), Frankfurt (G2AA.F), München (G2AA.MU), Düsseldorf (G2AA.DU).
Vifor Pharma AG is a Swiss pharmaceutical company specializing in the research, development, and marketing of medicines for patients with kidney diseases, iron deficiency anemia, and other important therapeutic areas. The company operates various divisions worldwide and is a leading provider of products in the healthcare industry.
Liikevaihtoa ei voida laskea Vifor Pharma:lle tällä hetkellä.
Voittoa ei voida laskea Vifor Pharma:lle tällä hetkellä.
P/E-suhdetta ei voida laskea Vifor Pharma:lle tällä hetkellä.
P/S-suhdetta ei voida laskea Vifor Pharma:lle tällä hetkellä.
Vifor Pharma:n Eulpool-laatuscore on 3/10.
Vifor Pharma:n ISIN on CH0364749348. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Vifor Pharma:n WKN on A2DRZ4. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Vifor Pharma:n ticker on VIFN.SW. Tämä pörssinoteeraus käytetään Vifor Pharma-osakkeiden kauppaan pörssissä.
Vifor Pharma osake
Vifor Pharma vertaisryhmä
Vifor Pharma Ticker
Vifor Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi Vifor Pharma:sta
Meidän osakeanalyysimme Vifor Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Vifor Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: